Company Overview of EpiVax, Inc.
EpiVax, Inc. is a biotechnology company that engages in the development and implementation of computational immunology tools. It provides interactive protein screening and reengineering interface for Web-based immunogenicity screening; and pre-deimmunization of a functional therapeutic report that is a concise description of a protein therapeutic candidate’s immunogenic potential. The company also offers EpiMatrix high throughput antibody immunogenicity prediction report that gives an overall assessment of potential clinical immunogenicity for a large set of antibody candidates; and Chinese hamster ovary protein predicted immunogenicity, an informatics tool to assess the immunogenic risk of ...
146 Clifford Street
Providence, RI 02903
Founded in 1998
Key Executives for EpiVax, Inc.
Founder, Chief Executive Officer and Chief Scientific Officer
Chief Operating Officer and Chief Information Officer
Head of Marketing and Business Development
Director of Molecular Immunology
Compensation as of Fiscal Year 2015.
EpiVax, Inc. Key Developments
Ipsen and EpiVax, Inc. Collaborate to Produce Next Generation Botulinum Toxins
Oct 26 15
Ipsen and EpiVax, Inc. announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics. Ipsen is actively developing an innovative platform of novel neurotoxin derived therapeutics, including TSI, that is opening up new therapeutic opportunities to address various medical conditions with unmet need. EpiVax will move the program forward, continuing potential product development for clinical use in neuromuscular health and aesthetic treatments. EpiVax will present the results of the research program so far conducted at the upcoming IBRCC 2015 conference on botulinum neurotoxins, in Frederick, Maryland. EpiVax applied its proprietary T cell epitope modification technology ISPRI to generate an engineered BoNT sequence. This platform program employs two key technologies developed and perfected by EpiVax: deimmunization and tolerization.
EpiVax, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
EpiVax, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries